NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
He Liu: The Shift in China’s Medtech Sector is Truly a Game-Changer
He Liu/LinkedIn
Nov 28, 2025, 22:58

He Liu: The Shift in China’s Medtech Sector is Truly a Game-Changer

He Liu, Chief Executive Officer at IMPELINNO GmbH, reposted from China Medtech Radar on LinkedIn:

”The shift in China’s Medtech sector is truly a game-changer, and our latest intelligence report, “The Surgeon-Engineered Solution,” captures the pivot point.

We are witnessing a fundamental move from being a cost-driven “Manufacturing” hub to a high-value “Intelligent Manufacturing” powerhouse, driven by the Med-Eng Integration model.

This means Chinese urgeons are now the primary nnovators, using their deep clinical insights to architect superior, clinical-driven devices like the ValveClamp® for TEER, MissilEX® thrombectomy and beyond, which exemplify the competitive landscape in China’s Medtech Innovation ecosystem.

I invite you to read the full analysis and engage with us: How can we best collaborate to plug into this high-velocity ecosystem? Let’s drive the future of MedTech together.”

Quoting China Medtech Radar‘s post:

”China’s medtech innovation model is undergoing a seismic shift!

The evolution of China’s medtech innovation from a cost-driven model to a clinical-led ecosystem warrants strategic consideration from the global medtech community.

We are excited to share our latest intelligence report, “The Surgeon-Engineered Solution,” which provides unique insight into the driving force behind China’s move from “Manufacturing” to “Intelligent Manufacturing.”

Key Takeaways for Global Stakeholders:

  1. The Surgeon as the Innovator: Chinese physicians are no longer just users; they are the source of medtech innovation. Their deep, clinical insights into unmet clinical needs are defining product development from the ground up, creating “China Solutions” to real-world problems.
  2. Med-Eng Integration: This is a highly efficient “Clinical-Engineering-Industry-Policy” ecosystem. It means surgeons and engineers collaborate from Day One to solve clinical pain points, leading to rapid RandD and shorter time-to-market.
  3. From Manufacturing to IntelligentManufacturing: This is the shift from a cost-focused, often imitative production model to a high-value, data-driven system utilizing AI and robotics to achieve breakthroughs in precision and quality.
  4. Real-World Success: Learn how this model has led to breakthroughs in China’s medtech like the Valve Clamp, Mitral Clip System (democratizing advanced repair), the MissilEX Intracranial Thrombectomy Device (demonstrating superior first-pass recanalization rates) and the Orthopedic Surgical Robot.

The competitive landscape in China’s medtch is being redefined.

For global medtech stakeholders, understanding this clinically-driven model is critical for successful internationalcollaboration and marketstrategy.

We invite you to read our exclusive analysis and join the conversation on fostering a collaborative future for medtechinnovation between China and the world.”

Read the full article here.

He Liu: The Shift in China's Medtech Sector is Truly a Game-Changer

Stay updated with Hemostasis Today.

China He Liu Health Hematology Hemostasis Hemostasis Today Medicine MedTech MissilEX Mitral Clip Surgeon-Engineered Solution TEER thrombosis Valve Clamp ValveClamp
NewsFeed